Phase I trials of targeted anticancer drugs: a need to refocus
As cancer therapy progresses through the development of molecularly targeted drugs, the focus of Phase I trials needs to shift towards investigating end points that could guide more effective trial design, dosing and choice of tumour setting for Phase II studies.
Gespeichert in:
| Veröffentlicht in: | Nature reviews. Drug discovery 2012-12, Vol.11 (12), p.889-890 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 890 |
|---|---|
| container_issue | 12 |
| container_start_page | 889 |
| container_title | Nature reviews. Drug discovery |
| container_volume | 11 |
| creator | Borden, Ernest C. Dowlati, Afshin |
| description | As cancer therapy progresses through the development of molecularly targeted drugs, the focus of Phase I trials needs to shift towards investigating end points that could guide more effective trial design, dosing and choice of tumour setting for Phase II studies. |
| doi_str_mv | 10.1038/nrd3909 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1399903556</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A311718003</galeid><sourcerecordid>A311718003</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-733208882ee01c651db8308fa5c3992979b28fbdf3538dd6a30e5e0f3e571eb93</originalsourceid><addsrcrecordid>eNptkcFrFTEQxoNYbK3ifyABD3p5dSbZ3SQeCqWoLRTqQc8hm0yeW95LarJ78L83jz5bLSWHhJnf9zGTj7E3CCcIUn9MJUgD5hk7wk51K1S6e37_VsMhe1nrDQAOqMQLdigkGgUCjtjpt5-uEr_kc5ncpvIc-ezKmmYK3KV58i55KjyUZV0_cccTtcaceaGY_VJfsYPYZPR6fx-zH18-fz-_WF1df708P7ta-R70vFJSCtBaCyJAP_QYRi1BR9d7aYwwyoxCxzFE2UsdwuAkUE8QJfUKaTTymH24870t-ddCdbbbqXrabFyivFSLzcaA7Puhoe8eoTd5KalNZ1HoDoXqUD5Qa7chO6WY5-L8ztSeSUSFGmBHnTxBtRNoO_mcKE6t_p_g_Z3Al1xr-yR7W6atK78tgt0lZfdJNfLtfsxl3FK45_5G87Byba20pvLPHo-8_gAzYJcR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1284127413</pqid></control><display><type>article</type><title>Phase I trials of targeted anticancer drugs: a need to refocus</title><source>MEDLINE</source><source>Nature</source><source>Alma/SFX Local Collection</source><creator>Borden, Ernest C. ; Dowlati, Afshin</creator><creatorcontrib>Borden, Ernest C. ; Dowlati, Afshin</creatorcontrib><description>As cancer therapy progresses through the development of molecularly targeted drugs, the focus of Phase I trials needs to shift towards investigating end points that could guide more effective trial design, dosing and choice of tumour setting for Phase II studies.</description><identifier>ISSN: 1474-1776</identifier><identifier>EISSN: 1474-1784</identifier><identifier>DOI: 10.1038/nrd3909</identifier><identifier>PMID: 23197020</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>67 ; 692/699/67/1059/602 ; Antimitotic agents ; Antineoplastic agents ; Antineoplastic Agents - adverse effects ; Biomedical and Life Sciences ; Biomedicine ; Biotechnology ; Cancer Research ; Clinical trials ; Clinical Trials, Phase I as Topic ; comment ; Humans ; Medicinal Chemistry ; Molecular Medicine ; Neoplasms - drug therapy ; Pharmacology/Toxicology ; Research Design ; Safety and security measures ; Testing</subject><ispartof>Nature reviews. Drug discovery, 2012-12, Vol.11 (12), p.889-890</ispartof><rights>Springer Nature Limited 2012</rights><rights>COPYRIGHT 2012 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Dec 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-733208882ee01c651db8308fa5c3992979b28fbdf3538dd6a30e5e0f3e571eb93</citedby><cites>FETCH-LOGICAL-c508t-733208882ee01c651db8308fa5c3992979b28fbdf3538dd6a30e5e0f3e571eb93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23197020$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Borden, Ernest C.</creatorcontrib><creatorcontrib>Dowlati, Afshin</creatorcontrib><title>Phase I trials of targeted anticancer drugs: a need to refocus</title><title>Nature reviews. Drug discovery</title><addtitle>Nat Rev Drug Discov</addtitle><addtitle>Nat Rev Drug Discov</addtitle><description>As cancer therapy progresses through the development of molecularly targeted drugs, the focus of Phase I trials needs to shift towards investigating end points that could guide more effective trial design, dosing and choice of tumour setting for Phase II studies.</description><subject>67</subject><subject>692/699/67/1059/602</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Cancer Research</subject><subject>Clinical trials</subject><subject>Clinical Trials, Phase I as Topic</subject><subject>comment</subject><subject>Humans</subject><subject>Medicinal Chemistry</subject><subject>Molecular Medicine</subject><subject>Neoplasms - drug therapy</subject><subject>Pharmacology/Toxicology</subject><subject>Research Design</subject><subject>Safety and security measures</subject><subject>Testing</subject><issn>1474-1776</issn><issn>1474-1784</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkcFrFTEQxoNYbK3ifyABD3p5dSbZ3SQeCqWoLRTqQc8hm0yeW95LarJ78L83jz5bLSWHhJnf9zGTj7E3CCcIUn9MJUgD5hk7wk51K1S6e37_VsMhe1nrDQAOqMQLdigkGgUCjtjpt5-uEr_kc5ncpvIc-ezKmmYK3KV58i55KjyUZV0_cccTtcaceaGY_VJfsYPYZPR6fx-zH18-fz-_WF1df708P7ta-R70vFJSCtBaCyJAP_QYRi1BR9d7aYwwyoxCxzFE2UsdwuAkUE8QJfUKaTTymH24870t-ddCdbbbqXrabFyivFSLzcaA7Puhoe8eoTd5KalNZ1HoDoXqUD5Qa7chO6WY5-L8ztSeSUSFGmBHnTxBtRNoO_mcKE6t_p_g_Z3Al1xr-yR7W6atK78tgt0lZfdJNfLtfsxl3FK45_5G87Byba20pvLPHo-8_gAzYJcR</recordid><startdate>20121201</startdate><enddate>20121201</enddate><creator>Borden, Ernest C.</creator><creator>Dowlati, Afshin</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20121201</creationdate><title>Phase I trials of targeted anticancer drugs: a need to refocus</title><author>Borden, Ernest C. ; Dowlati, Afshin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-733208882ee01c651db8308fa5c3992979b28fbdf3538dd6a30e5e0f3e571eb93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>67</topic><topic>692/699/67/1059/602</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Cancer Research</topic><topic>Clinical trials</topic><topic>Clinical Trials, Phase I as Topic</topic><topic>comment</topic><topic>Humans</topic><topic>Medicinal Chemistry</topic><topic>Molecular Medicine</topic><topic>Neoplasms - drug therapy</topic><topic>Pharmacology/Toxicology</topic><topic>Research Design</topic><topic>Safety and security measures</topic><topic>Testing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Borden, Ernest C.</creatorcontrib><creatorcontrib>Dowlati, Afshin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Source</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Nature reviews. Drug discovery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Borden, Ernest C.</au><au>Dowlati, Afshin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase I trials of targeted anticancer drugs: a need to refocus</atitle><jtitle>Nature reviews. Drug discovery</jtitle><stitle>Nat Rev Drug Discov</stitle><addtitle>Nat Rev Drug Discov</addtitle><date>2012-12-01</date><risdate>2012</risdate><volume>11</volume><issue>12</issue><spage>889</spage><epage>890</epage><pages>889-890</pages><issn>1474-1776</issn><eissn>1474-1784</eissn><abstract>As cancer therapy progresses through the development of molecularly targeted drugs, the focus of Phase I trials needs to shift towards investigating end points that could guide more effective trial design, dosing and choice of tumour setting for Phase II studies.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>23197020</pmid><doi>10.1038/nrd3909</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1474-1776 |
| ispartof | Nature reviews. Drug discovery, 2012-12, Vol.11 (12), p.889-890 |
| issn | 1474-1776 1474-1784 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1399903556 |
| source | MEDLINE; Nature; Alma/SFX Local Collection |
| subjects | 67 692/699/67/1059/602 Antimitotic agents Antineoplastic agents Antineoplastic Agents - adverse effects Biomedical and Life Sciences Biomedicine Biotechnology Cancer Research Clinical trials Clinical Trials, Phase I as Topic comment Humans Medicinal Chemistry Molecular Medicine Neoplasms - drug therapy Pharmacology/Toxicology Research Design Safety and security measures Testing |
| title | Phase I trials of targeted anticancer drugs: a need to refocus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T06%3A10%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20I%20trials%20of%20targeted%20anticancer%20drugs:%20a%20need%20to%20refocus&rft.jtitle=Nature%20reviews.%20Drug%20discovery&rft.au=Borden,%20Ernest%20C.&rft.date=2012-12-01&rft.volume=11&rft.issue=12&rft.spage=889&rft.epage=890&rft.pages=889-890&rft.issn=1474-1776&rft.eissn=1474-1784&rft_id=info:doi/10.1038/nrd3909&rft_dat=%3Cgale_proqu%3EA311718003%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1284127413&rft_id=info:pmid/23197020&rft_galeid=A311718003&rfr_iscdi=true |